恩威斯塔控股
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Instruments & Supplies
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 恩威斯塔控股 (NVST) | 3.68B | 39.48 | 1.20 | 0.00% |
| Intuitive Surgical (ISRG) | 150.74B | 48.93 | 8.30 | 0.00% |
| Becton Dickinson & Co (BDX) | 52.23B | 57.93 | 2.14 | 2.19% |
| ResMed (RMD) | 33.61B | 22.91 | 5.10 | 1.00% |
| Alcon (ALC) | 31.99B | 50.52 | 1.48 | 0.53% |
| Medline (MDLN) | 31.55B | 68.24 | 2.73 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算7.5%。
合理价值
Envista Holdings Corp earns a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 5% discount to our quantitative fair value estimate of $24.62 per share, which is reinforced by this estimate's low uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The company's valuation metrics bolster our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 80.6%, which lies in the top 40% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.
The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's sales yield of 73.3%, a core component of profitability, falls in the top 45% compared with peers globally. This company has a robust ability to generate sales without much capital investment, freeing up more capital to be returned to shareholders in the long run. This characteristic further promotes our favorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
经济护城河
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
恩威斯塔控股 讨论区 0 条评论